Elevated nephrogenous cyclic adenosine monophosphate to monitor early renal osteodystrophy

A. M. Krensky, W. E. Harmon, J. R. Ingelfinger, J. A. Kirkpatrick, W. E. Grupe

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Radiographs, serum chemistries, parathyroid hormone (PTH), and nephrogenous cyclic adenosine monophosphate (cAMP) were evaluated in thirty-two children with normal serum creatinine, chronic renal insufficiency, chronic hemodialysis, and transplantation. Nephrogenous cAMP increases linearly with creatinine, and there is a good correlation (r = 0.89) between immunoreactive PTH (iPTH) and nephrogenous cAMP except for patients with severe renal insufficiency or requiring chronic hemodialysis. Elevated nephrogenous cAMP is evidence for metabolic bone disease earlier than usually recognized. Early measurements of iPTH and nephrogenous cAMP could ensure early therapeutic intervention which might alleviate renal osteodystrophy in chronic renal insufficiency and transplant patients.

Original languageEnglish (US)
Pages (from-to)245-250
Number of pages6
JournalClinical Nephrology
Issue number5
StatePublished - Dec 29 1981

ASJC Scopus subject areas

  • Nephrology


Dive into the research topics of 'Elevated nephrogenous cyclic adenosine monophosphate to monitor early renal osteodystrophy'. Together they form a unique fingerprint.

Cite this